drugset / Trial / NCT02280018

A Safety, Tolerability and Pharmacokinetics Study of a Single Intravenous Dose of JNJ-49122944 in Healthy Male Participants

NCT02280018 ↗

Phase 1 Completed 12 enrolled Janssen Research & Development, LLC
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to assess the safety, tolerability, and pharmacokinetics (the study of the way a drug enters and leaves the blood and tissues over time) of JNJ-49122944 in healthy male participants after a single intravenous (\[IV\] within a vein) dose administration.

Timeline

Start
2014-11
Primary completion
2014-12
Completion
2014-12

Drugs

EvaluationDrugModalityDoseRoute
Subject JNJ-49122944 Unknown 5 mg Intravenous

Indications

No indication recorded.